Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 205
- Registration Number
- NCT01186861
- Locations
- 🇺🇸
Site US10004, Greensboro, North Carolina, United States
🇵🇱Site PL48005, Szczecin, Poland
🇷🇴Site RO40005, Alba Iulia, Romania
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
- Conditions
- Interventions
- First Posted Date
- 2010-08-16
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Karen D. Wright MD
- Target Recruit Count
- 53
- Registration Number
- NCT01182350
- Locations
- 🇺🇸
Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT01180959
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 11
- Registration Number
- NCT01174043
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 347
- Registration Number
- NCT01161173
A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT01153984
- Locations
- 🇷🇴
Spitalul de Boli Cronice Sf. Luca, Bucharest, Romania
🇷🇴Emergency University Bucharest Hospital; Oncology Department, Bucharest, Romania
🇷🇴ONCOMED - Medical Centre, Timisoara, Romania
A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
- Conditions
- Interventions
- First Posted Date
- 2010-05-27
- Last Posted Date
- 2010-05-27
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT01131429
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 83
- Registration Number
- NCT01130519
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 43
- Registration Number
- NCT01130753
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck
- Conditions
- Interventions
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 25
- Registration Number
- NCT01116336
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.